Digital Respiratory Devices Market Analysis

Global Digital Respiratory Devices Market Overview

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Digital Respiratory Devices Market Trends

• Increasing prevalence of respiratory disorders, such as COPD, TB, asthma, and sleep apnea is driving the market growth

The considerable rise in the prevalence of severe chronic respiratory diseases (CRDs) like bronchial asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, lung disorders, and pulmonary hypertension (PH) is responsible for the market growth. A growing senior population, tobacco usage, increased air pollution, and occupational exposure to dust in the mining, forestry, and agricultural industries all contribute to a steadily rising risk of acquiring CRDs. As a result, the market for respiratory management tools is expanding quickly. Clinical testing, regulatory processes, and post-approval operations have become more difficult as a result of the COVID-19 pandemic. This is primarily due to challenges with patient enrollment, treatment, and recruitment for clinical research.

However, it is projected that the use of smart inhalers will rise in the post-pandemic era as healthcare providers resort to linked medical devices to guarantee that patients receive the best care and advice available, regardless of the situation. This is due to the fact that many patients suffered since they were unable to receive consultations and treatments in person due to the pandemic's restrictions. 

The pandemic illustrated just how deadly respiratory infections and diseases can become if not promptly and adequately managed. According to the research that is currently available, digital inhalers help asthma and COPD patients better manage their medications and receive direct clinical care. The benefits of improved medication adherence have the potential to improve clinical outcomes and reduce the need for more expensive or complex therapies like biologics.

Additionally, positive results were seen with the usage of Adherium's smart inhaler system in a 12-month controlled research that was carried out in January 2017 at the Sheffield Children's Hospital in the United Kingdom. Less hospitalizations, better medication adherence, and fewer doctor visits were some of the beneficial medical outcomes. The global market is being driven by an increasing number of key developments in digital respiratory technology. For instance, FindAir medical's FindAir ONE smart inhaler device, which has received CE certification, is available to the general public in Europe as of January 2019. 

To increase the effectiveness of drug management, an increasing number of enterprises are adding digital technologies into their products. For instance, HeroTracker Sense was introduced by Aptar Pharma in April 2022. A standard metered dosage inhaler (pMDI) is transformed into a smart linked healthcare device by this revolutionary digital respiratory health solution. Thus, driving the Digital Respiratory Devices market revenue.

Digital Respiratory Devices Market Segment Insights

Digital Respiratory Devices Product Insights

The Market segments of Digital Respiratory Devices, based on Product, includes smart inhalers & nebulizers and sensors & apps. Smart inhalers & nebulizers segment dominated the global market in 2022. It is anticipated that the rising air pollution levels, increasing prevalence of asthma and other respiratory diseases, and expanding desire for digital respiratory devices would all contribute to this demand. Furthermore, it has been demonstrated that individuals with COPD and asthma adhere more frequently while using smart inhalers. Smart inhalers also offer more effective assistance and keep track of the medicine inhalation approach when compared to traditional inhalers.

Digital Respiratory Devices Indication Insights

The Digital Respiratory Devices Market segmentation, based on Indication, includes asthma, COPD, and other diseases. COPD segment dominated the global market in 2022. 200 million individuals worldwide suffer with COPD.  Additionally, respiratory disorders account for slightly more than 8% of all chronic diseases worldwide. By 2030, COPD will overtake ischemic heart disease and HIV/AIDS to become the fourth-leading causes of mortality, according to a World Health Organization projection made in 2020.

Digital Respiratory Devices Distribution Channel Insights

The Market segmentation of Digital Respiratory Devices, based on Distribution Channel, includes hospital pharmacies, retail pharmacies, and online pharmacies. Hospital pharmacies segment dominated the Digital Respiratory Devices Market in 2022. The elderly population frequently receives medical care for a variety of chronic respiratory ailments, and they buy medication for these conditions from hospital pharmacies. Hospital pharmacies also provide medical staff with medication supplies so that patients can get their drugs quickly.

Digital Respiratory Devices End Use Insights

The Market segmentation of Digital Respiratory Devices, based on End Use, includes hospitals, homecare settings, and other settings. Hospitals segment dominated the Digital Respiratory Devices Market in 2022. Over the coming years, increased public-private partnerships, quick advancements in healthcare infrastructure, and greater access to healthcare services are all expected to cause a major increase in the market for hospitals. Hospitals, homecare settings, and other settings make up the market segments.

Figure 1: Digital Respiratory Devices Market, by End Use, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Digital Respiratory Devices Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North America Digital Respiratory Devices Market dominated this market in 2022 (45.80%). Asthma, COPD, and other chronic respiratory disorders are becoming more prevalent, which is the cause of this. More than 25 million Americans suffer with asthma. 

Additionally, 14.8 million individuals in the United States have COPD, and the disease claims the lives of 150,000 Americans each year, or one every four minutes. Further, the U.S. market of Digital Respiratory Devices held the largest market share, and the Canada market of Digital Respiratory Devices was the fastest growing market in the North America region.Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: DIGITAL RESPIRATORY DEVICES MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe Digital Respiratory Devices market accounted for the healthy market share in 2022. During the projection period, it is anticipated that significant advancements in digital respiratory products and their rising acceptance and accuracy will drive market expansion. Further, the German market of Digital Respiratory Devices held the largest market share, and the U.K market of Digital Respiratory Devices was the fastest growing market in the European region

The Asia Pacific Digital Respiratory Devices market is expected to register significant growth from 2023 to 2032. Growing COPD and asthma incidence rates in China and India are mainly blame for this expansion. The number one cause of impairment in China is COPD, which is also a significant public health concern. AstraZeneca's Bevespi Aerosphere, which is used to treat COPD symptoms such chronic bronchitis and/or emphysema, obtained approval in China in May 2020. Moreover, China’s market of Digital Respiratory Devices held the largest market share and the Indian market of Digital Respiratory Devices was the fastest growing market in the Asia-Pacific region.

Digital Respiratory Devices Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the market of Digital Respiratory Devices, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Digital Respiratory Devices industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Digital Respiratory Devices industry to benefit clients and increase the market sector. In recent years, the Digital Respiratory Devices industry has offered some of the most significant advantages to medicine. 

Major players in the Digital Respiratory Devices market, including COHERO Health Inc, Cognita Labs, Adherium Limited, Amiko Digital Health Limited, Teva Pharmaceuticals Industries Ltd., Propeller Health, Novartis AG, Pneuma Respiratory Inc., 3M Health Care Limited, AireHealth, Inc., and FindAir Sp. z o.o, are attempting to increase market demand by investing in research and development Products.

A healthcare firm called Novartis AG (Novartis) specializes in the development, production, and marketing of prescription and over-the-counter medicines, as well as products for eye care. In addition to others, it offers medicines for the treatment of solid tumors, immunological disorders, infections, cardiovascular illness, dermatological issues, neurological disorders, ophthalmic and respiratory diseases, cancer, and neurological disorders. 

Through Sandoz, the business provides biosimilars and generic medications. Through the Novartis Institutes for BioMedical Research (NIBR), Novartis carries out research in a number of disease-related fields. In the Americas, Europe, the Middle East, Africa, and Asia-Pacific, the corporation has a network of subsidiaries and offices. Basel, Switzerland serves as the headquarters of Novartis.

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical firm that focuses on the development, manufacturing, and marketing of a variety of prescription medications. It creates goods for the treatment of ailments like cancer, autoimmune, infectious, neurological, and respiratory, cardiovascular, renal, and metabolic problems. Vaccines, prescription medications, and biologics are all part of the company's product line. Through distributors, local representative offices, and wholly-owned local marketing firms, AstraZeneca offers its products. 

The business sells its goods to general practitioners and specialists in medicine. Operating regions for the corporation include Europe, the Americas, Asia, Africa, and Australasia. The U.K.'s Cambridge, in Cambridgeshire, serves as the company's headquarters. AstraZeneca's Bevespi Aerosphere, which is used to treat COPD symptoms such chronic bronchitis and/or emphysema, obtained approval in China in May 2020.

Key Companies in the market of Digital Respiratory Devices include

• COHERO Health Inc.


• Cognita Labs


• Adherium Limited


• Amiko Digital Health Limited


• Teva Pharmaceuticals Industries Ltd.


• Propeller Health


• Novartis AG


• Pneuma Respiratory Inc.


• 3M Health Care Limited


• AireHealth, Inc.


• FindAir Sp. z o.o

Digital Respiratory Devices Industry Developments

July 2022 In order to provide access to pulse oximetry for anesthesia and critical care, Smile Train, Inc. and their long-time partner Lifebox introduced the Lifebox-Smile Train pulse oximeter.

Digital Respiratory Devices Market Segmentation

Digital Respiratory Devices Product Outlook

• Smart Inhalers & Nebulizers


• Sensors & Apps

Digital Respiratory Devices Indication Outlook

• Asthma


• COPD


• Other Diseases

Digital Respiratory Devices Distribution Channel Outlook

• Hospital Pharmacies


• Retail Pharmacies


• Online Pharmacies

Digital Respiratory Devices End Use Outlook

• Hospitals


• Homecare Settings


• Other Settings

Digital Respiratory Devices Regional Outlook

• North America
  
  
  
  • U.S.
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America